

## References

1. McFarland HF, Martin R. Multiple sclerosis: a complicated picture of autoimmunity. *Nat Immunol.* 2007;8:913-919.
2. Trapp BD, Peterson J, Ransohoff RM, et al. Axonal transection in the lesions of multiple sclerosis. *N Engl J Med.* 1998;338:278-285.
3. International Multiple Sclerosis Genetics Consortium. Risk alleles for multiple sclerosis identified by a genomewide study. *N Engl J Med.* 2007;357:851-862.
4. Alonso A, Hernán MA. Temporal trends in the incidence of multiple sclerosis: a systematic review. *Neurology.* 2008;71:129-135.
5. Debouverie M, Pittion-Vouyovitch S, Louis S, et al. Increasing incidence of multiple sclerosis among women in Lorraine, Eastern France. *Mult Scler.* 2007;13:962-967.
6. Orton SM, Herrera BM, Yee IM, et al. Sex ratio of multiple sclerosis in Canada: a longitudinal study. *Lancet Neurol.* 2006;5:932-936.
7. Cassels C. Multiple sclerosis prevalence increasing faster among women than men. Medscape Medical News. Medscape Today Web site. Available at: <http://www.medscape.com/viewarticle/555620>. Accessed October 29, 2008.
8. Raghuwanshi A, Joshi SS, Christakos S. Vitamin D and multiple sclerosis. *J Cell Biochem.* 2008;105:338-343.
9. Ascherio A, Munger KL. Environmental risk factors for multiple sclerosis. Part I: the role of infection. *Ann Neurol.* 2007;61:288-299.
10. Lünemann JD, Edwards N, Muraro PA, et al. Increased frequency and broadened specificity of latent EBV nuclear antigen-1-specific T cells in multiple sclerosis. *Brain.* 2006;129:1493-1506.
11. Rand KH, Houck H, Denslow ND, Heilman KM. Epstein-Barr virus nuclear antigen-1 (EBNA-1) associated oligoclonal bands in patients with multiple sclerosis. *J Neurol Sci.* 2000;173:32-39.
12. Miller DH, Grossman RI, Reingold SC, McFarland HF. The role of magnetic resonance techniques in understanding and managing multiple sclerosis. *Brain.* 1998;121:3-24.
13. Food and Drug Administration. Information on gadolinium-containing contrast agents. Available at: <http://www.fda.gov/cder/drug/infopage/gcca/default.htm>. Accessed October 29, 2008.

14. Wingerchuk DM, Lennon VA, Pittock SJ, et al. Revised diagnostic criteria for neuromyelitis optica. *Neurology*. 2006;66:1485-1489.
15. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. *Ann Neurol*. 2005;58:840-846.
16. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. *Neurology*. 1996;46:907-911.
17. Sayao AL, Devonshire V, Tremlett H. Longitudinal follow-up of “benign” multiple sclerosis at 20 years. *Neurology*. 2007;68:496-500.
18. Comi G, Filippi M, Barkhof F, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. *Lancet*. 2001;357:1576-1582.
19. Jacobs LD, Beck RW, Simon JH, et al. Intramuscular interferon  $\beta$ -1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. *N Engl J Med*. 2000;343:898-904.
20. Kappos L, Polman CH, Freedman MS, et al. Treatment with interferon  $\beta$ -1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. *Neurology*. 2006;67:1242-1249.
21. Comi G, et al. PRECISE clinical trial. Presented at: 60th Annual Meeting of the American Academy of Neurology; April 12-19, 2008; Chicago, IL.